Status:
COMPLETED
Behavioral and Cognitive Therapies for Auditory Hallucination Management
Lead Sponsor:
University Hospital, Toulouse
Conditions:
Chronic Psychosis
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
The present study wants to evaluate the efficacy of a short psychoeducational type group intervention and Cognitive behavioral therapy (CBT) 3rd wave on the severity of hallucinatory Acoustico-Verbal ...
Eligibility Criteria
Inclusion
- Schizophrenic disorders, schizo-affective disorders
- Suffering from persistent HAV
- No change in symptomatology for 3 months.
- No anticipated change in antipsychotic treatment (anti-hallucinatory): olanzapine, risperidone, amisulpride, quetiapine, aripiprazole, loxapine, haloperidol, clopixol, modecate, nozinan, cyamemazine, piportil, clozapine
- Major patient, or major incompetent.
Exclusion
- Mental retardation
- Subject participating in another search including an exclusion period still in progress at pre-inclusion
Key Trial Info
Start Date :
December 13 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2020
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT03348787
Start Date
December 13 2017
End Date
June 30 2020
Last Update
July 30 2020
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Lannemezan Hospital
Lannemezan, France, 65300
2
Lavaur Hospital
Lavaur, France, 81502
3
Sainte-Marie de Rodez Hospital
Rodez, France, 12032
4
Ariège-Couserans Hospital
Saint-Lizier, France, 09190